分组1 - Cyclo Therapeutics reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.29 per share a year ago, indicating a surprise of -52.94% [1] - The company posted revenues of $0.23 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 24.52%, and down from $0.5 million in the same quarter last year [2] - Cyclo Therapeutics shares have declined approximately 54.7% since the beginning of the year, contrasting with the S&P 500's gain of 25.5% [3] 分组2 - The earnings outlook for Cyclo Therapeutics is uncertain, with current consensus EPS estimates at -$0.19 on $0.21 million in revenues for the upcoming quarter and -$0.72 on $0.89 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] - The estimate revisions trend for Cyclo Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6]
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates